Murugesan Raju
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Murugesan Raju has a total of 790 co-authors. Here are the top co-authors by number of shared publications:
- Chi-Ren Shyu
University of Missouri
53 shared publications - Jonathan B. Mitchem
MU Institute for Data Science and Informatics, University of Missouri, Columbia, MO 65212, USA
51 shared publications - Jussuf T. Kaifi
University of Missouri
51 shared publications - Guangfu Li
Department of Surgery, University of Missouri, Columbia, Missouri, USA
50 shared publications - Wesley C. Warren
Bond Life Sciences Center, University of Missouri, Columbia, USA
50 shared publications - Yariswamy Manjunath
Department of Surgery, Ellis Fischel Cancer Center, Roy Blunt NextGen Precision Health Institute, University of Missouri, Columbia, Missouri. 1
50 shared publications
Latest Publications
- Open Access
Neuronal Gene Architecture in Cancer borealis Revealed by Long-Read Genome Assembly and Deep Transcriptomic Analysis
Understanding the underlying neuronal function in non-model organisms requires accurate resolution of gene structure and transcript diversity. Here, we present a comprehensive genome annotation for the Jonah crab ( Cancer borealis ), a key experimental system in crustacean neurobiology, with a particular focus on transcriptome-supported neuronal gene architecture. By integrating long-read genome assembly with extensive transcriptomic evidence, we reconstructed gene models with high confidence, enabling detailed characterization of exonintron organization, alternative splicing, and isoform diversity across gene families. Functional classification revealed extensive representation of neural-associated gene classes, including ion channels and receptors, transporters, enzymes, zinc finger proteins, histones, structural proteins, and cell adhesion molecules, alongside a large set of previously uncharacterized genes. In this study we particularly focused on the neuronal and ion channel gene families known to underlie circuit-level neuronal function in C. borealis . We provide an in-depth analysis of 87 genes spanning 17 neural-related gene families and 41 neuropeptide receptors, detailing chromosomal localization, gene length, exonintron configuration, and transcript-supported isoform structure. For many of these genes, transcriptomic data confirmed expression and refined coding boundaries. Comparisons with existing transcriptomic datasets demonstrate strong concordance in gene expression patterns while also revealing novel transcripts and expanded gene family members not previously annotated. Together, this genome and transcriptome-integrated annotation establishes a high-resolution framework for studying neuronal gene organization in C. borealis . This resource enables direct connections between gene architecture, transcript diversity, and neural function, supporting future investigations in crustacean neurogenomics, comparative genomics, and the evolution of nervous system complexity.
Open AccessNeuronal Gene Architecture in Cancer borealis Revealed by Long-Read Genome Assembly and Deep Transcriptomic Analysis
Understanding the underlying neuronal function in non-model organisms requires accurate resolution of gene structure and transcript diversity. Here, we present a comprehensive genome annotation for the Jonah crab ( Cancer borealis ), a key experimental system in crustacean neurobiology, with a particular focus on transcriptome-supported neuronal gene architecture. By integrating long-read genome assembly with extensive transcriptomic evidence, we reconstructed gene models with high confidence, enabling detailed characterization of exonintron organization, alternative splicing, and isoform diversity across gene families. Functional classification revealed extensive representation of neural-associated gene classes, including ion channels and receptors, transporters, enzymes, zinc finger proteins, histones, structural proteins, and cell adhesion molecules, alongside a large set of previously uncharacterized genes. In this study we particularly focused on the neuronal and ion channel gene families known to underlie circuit-level neuronal function in C. borealis . We provide an in-depth analysis of 87 genes spanning 17 neural-related gene families and 41 neuropeptide receptors, detailing chromosomal localization, gene length, exonintron configuration, and transcript-supported isoform structure. For many of these genes, transcriptomic data confirmed expression and refined coding boundaries. Comparisons with existing transcriptomic datasets demonstrate strong concordance in gene expression patterns while also revealing novel transcripts and expanded gene family members not previously annotated. Together, this genome and transcriptome-integrated annotation establishes a high-resolution framework for studying neuronal gene organization in C. borealis . This resource enables direct connections between gene architecture, transcript diversity, and neural function, supporting future investigations in crustacean neurogenomics, comparative genomics, and the evolution of nervous system complexity.
- Open Access
A novel dataset of 2,362 equine fecal microbiomes from eight veterinary teaching hospital on three continents reveals dominant effects of geography, breed, and disease
Horses and other equids are reliant on the gut microbiome for health, and studies have reported associations between certain clinical conditions and features of the fecal microbiome. However, research to date on the equine fecal microbiome has often relied on small sample sizes collected from single and relatively localized geographic regions. Previous work largely employs single timepoint analyses, or horses selected based on limited health criteria. To address these issues and expand our understanding of the core microbiome in health, and the changes associated with adverse outcomes, the Equine Gut Group (EGG) has collected and performed 16S rRNA sequencing on 2,362 fecal samples from 1,190 healthy and affected horses. Here we present the EGG database and demonstrate its utility in characterizing the equine microbiome in health and acute gastrointestinal disease. The EGG 16S rRNA database is a valuable resource to study the equine microbiome and its role in equine health.
Open AccessA novel dataset of 2,362 equine fecal microbiomes from eight veterinary teaching hospital on three continents reveals dominant effects of geography, breed, and disease
Horses and other equids are reliant on the gut microbiome for health, and studies have reported associations between certain clinical conditions and features of the fecal microbiome. However, research to date on the equine fecal microbiome has often relied on small sample sizes collected from single and relatively localized geographic regions. Previous work largely employs single timepoint analyses, or horses selected based on limited health criteria. To address these issues and expand our understanding of the core microbiome in health, and the changes associated with adverse outcomes, the Equine Gut Group (EGG) has collected and performed 16S rRNA sequencing on 2,362 fecal samples from 1,190 healthy and affected horses. Here we present the EGG database and demonstrate its utility in characterizing the equine microbiome in health and acute gastrointestinal disease. The EGG 16S rRNA database is a valuable resource to study the equine microbiome and its role in equine health.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary File S3 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary File S3. Differentially expressed genes between Resistant and Sensitive PDTOs.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File S3 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary File S3. Differentially expressed genes between Resistant and Sensitive PDTOs.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S9. Dose titration of epalrestat against PDTOs to determine the cytotoxicity.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S9. Dose titration of epalrestat against PDTOs to determine the cytotoxicity.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S3. Gene expression comparison between matched patient-derived tumor organoids (PDTOs) and patient primary tumors (PT) by whole transcriptome analysis.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S3. Gene expression comparison between matched patient-derived tumor organoids (PDTOs) and patient primary tumors (PT) by whole transcriptome analysis.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S12. Validation of AKR1B10 expression in an internal cohort of sensitive (n = 7) and resistance (n = 7) patient tumors to platinum-based doublet therapy.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S12. Validation of AKR1B10 expression in an internal cohort of sensitive (n = 7) and resistance (n = 7) patient tumors to platinum-based doublet therapy.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary File S4 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary File S4. Differentially expressed genes between resistant versus sensitive patient tumors (categorized based on PDTOs therapy outcome).
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary File S4 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary File S4. Differentially expressed genes between resistant versus sensitive patient tumors (categorized based on PDTOs therapy outcome).
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S7. Dose titration of carboplatin and paclitaxel against PDTOs to determine the cytotoxicity.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S7. Dose titration of carboplatin and paclitaxel against PDTOs to determine the cytotoxicity.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S13 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S13. Dose titration of commonly used cytotoxic agents against LUAC (n = 6) and LUSC (n = 6) cell lines.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S13 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S13. Dose titration of commonly used cytotoxic agents against LUAC (n = 6) and LUSC (n = 6) cell lines.
- Open Access
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S14 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S14. Dose titration of commonly used cytotoxic agents against AKR1B10 knocked down and scramble shRNA treated A549 cells.
- 3 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S14 from Targeting AKR1B10 by Drug Repurposing with Epalrestat Overcomes Chemoresistance in Non–Small Cell Lung Cancer Patient-Derived Tumor Organoids
Supplementary Figure S14. Dose titration of commonly used cytotoxic agents against AKR1B10 knocked down and scramble shRNA treated A549 cells.